0
Nov 10 (Reuters) – Johnson & Johnson: * JOHNSON & JOHNSON ANNOUNCES CAPLYTA (LUMATEPERONE) SHOWS SIGNIFICANT AND RAPID IMPROVEMENT IN BIPOLAR MANIA IN SECOND PIVOTAL PHASE 3 STUDY * JOHNSON & JOHNSON
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
